ArticleMethods in molecular biology (Clifton, N.J.)2026
Laser Capture Microdissection Followed by DNA Methylation Profiling.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laser capture microdissection (LCM) enables the precise isolation of morphologically defined cell populations, overcoming the confounding effects of tissue heterogeneity in DNA methylation analyses. However, the low DNA yield inherent to LCM-often derived from fewer than 1000 cells-challenges conventional bisulfite-based sequencing, which requires high DNA input and induces severe degradation. Here, we integrate LCM with Enzymatic Methyl-seq (EM-seq), a bisulfite-free, enzymatic conversion method that preserves DNA integrity by minimizing damage and reducing GC bias. Our optimized low-input library preparation protocols allow robust and reproducible methylation profiling from as few as 100 cells, with data quality comparable to that of bulk tissue samples. This strategy not only enables the isolation of tumor cells to uncover methylation signatures for early biomarker discovery and targeted therapies in oncology but also holds promise for advancing personalized medicine through patient-specific epigenetic profiling. Overall, our work establishes LCM-EM-seq as a scalable framework for spatially resolved, methylation-aware analyses of rare cell populations, opening new avenues for studying epigenetic heterogeneity in development and disease.
Indexed as
Identifiers
41629709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.